Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Cappuzzo

Showing results (131-140 of 275) with videos related to

Pageof 28
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|December 3, 2015
microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancersPierluigi Gasparini, Luciano Cascione, Lorenza Landi, et al.
Current Drug Targets|December 17, 2014
The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target?Francesco Passiglia, Nele Van Der Steen, Luis Raez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2016
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR MutationsBarbara Klughammer, Wolfram Brugger, Federico Cappuzzo, et al.
Cancers|April 23, 2022
Analysis of Molecular Biomarkers in Resected Early-Stage Non-Small Cells Lung Cancer: A Narrative ReviewFilippo Tommaso Gallina, Luca Bertolaccini, Daniele Forcella, et al.
Lung Cancer (Amsterdam, Netherlands)|October 8, 2013
Strategies for improving outcomes in NSCLC: a look to the futureRolf Stahel, Solange Peters, Paul Baas, et al.
Lung Cancer (Amsterdam, Netherlands)|February 9, 2010
Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP)Rolf Stahel, Paul Baas, Corinne Faivre-Finn, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2023
ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinomaFilippo Tommaso Gallina, Riccardo Tajè, Fabiana Letizia Cecere, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2007
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)Federico Cappuzzo, Claudia Ligorio, Claudio Ligorio, et al.
JTO Clinical and Research Reports|June 19, 2025
Erratum to 'Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC' [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100815]Federico Cappuzzo, Zanete Zvirbule, Ernesto Korbenfeld, et al.
JTO Clinical and Research Reports|April 18, 2025
Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLCFederico Cappuzzo, Zanete Zvirbule, Ernesto Korbenfeld, et al.
Pageof 28

Showing results (131-140 of 275) with videos related to

Sort By:
Pageof 28
Proceedings of the National Academy of Sciences of the United States of America|December 3, 2015
microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancersPierluigi Gasparini, Luciano Cascione, Lorenza Landi, et al.
Current Drug Targets|December 17, 2014
The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target?Francesco Passiglia, Nele Van Der Steen, Luis Raez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2016
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR MutationsBarbara Klughammer, Wolfram Brugger, Federico Cappuzzo, et al.
Cancers|April 23, 2022
Analysis of Molecular Biomarkers in Resected Early-Stage Non-Small Cells Lung Cancer: A Narrative ReviewFilippo Tommaso Gallina, Luca Bertolaccini, Daniele Forcella, et al.
Lung Cancer (Amsterdam, Netherlands)|October 8, 2013
Strategies for improving outcomes in NSCLC: a look to the futureRolf Stahel, Solange Peters, Paul Baas, et al.
Lung Cancer (Amsterdam, Netherlands)|February 9, 2010
Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP)Rolf Stahel, Paul Baas, Corinne Faivre-Finn, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2023
ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinomaFilippo Tommaso Gallina, Riccardo Tajè, Fabiana Letizia Cecere, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2007
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)Federico Cappuzzo, Claudia Ligorio, Claudio Ligorio, et al.
JTO Clinical and Research Reports|June 19, 2025
Erratum to 'Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC' [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100815]Federico Cappuzzo, Zanete Zvirbule, Ernesto Korbenfeld, et al.
JTO Clinical and Research Reports|April 18, 2025
Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLCFederico Cappuzzo, Zanete Zvirbule, Ernesto Korbenfeld, et al.
Pageof 28